The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery
Status:
RECRUITING
Trial end date:
2027-09-14
Target enrollment:
Participant gender:
Summary
The primary aim of this clinical trial is to investigate the effects of intravenous iron on recovery in mobility compared to the pre-fracture level in patients with a hip fracture
The main questions it aims to answer are:
It is hypothesize that intravenous iron will enhance gains in mobility and hereby recovery of mobility, increase hemoglobin (Hgb), lower fatigue, have a positive effect on skeletal muscles in the weeks and months after administration.
The primary objective is to compare the effect of a single dose of ferric derisomaltose (FDI) (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility, measured as the change from baseline in the New Mobility Score.
Participants will:
\- Receive either a single dose of intravenous FDI (20 mg/kg body weight) (and saline) or placebo (saline) at 1-5 days after surgery.
This trial will be conducted at three hospitals in Denmark, involving an anticipated 210 participants.
Phase:
PHASE4
Details
Lead Sponsor:
Soren Overgaard
Collaborators:
Copenhagen University Hospital at Herlev Musculoskeletal Statistics Unit, The Parker Institute Odense University Hospital Svendborg Hospital University Hospital Bispebjerg and Frederiksberg